Select therapeutic use:
Indications for MAKENA:
To reduce risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. Limitation of use: not intended for use in women with multiple gestations or other risk factors for preterm birth.
Begin treatment between 16 weeks 0 days and 20 weeks 6 days gestation. Inject slowly (over 1 min or longer) into upper outer quadrant of gluteus maximus. 250mg IM once weekly. Continue until Week 37 (through 36 weeks, 6 days) of gestation or delivery, whichever comes first.
<16yrs: not established.
Current or history of thrombosis or thromboembolic disorders. Known, suspected, or history of breast or other hormone-sensitive cancers. Undiagnosed abnormal genital bleeding. Cholestatic jaundice of pregnancy. Hepatic adenoma or carcinoma. Active hepatic disease. Uncontrolled hypertension.
Conditions aggravated by fluid retention (eg, preeclampsia, epilepsy, migraine, asthma, cardiac or renal dysfunction). Monitor prediabetes, diabetes, and depression. Discontinue if depression, thromboembolic events or allergic reactions occur. Reevaluate if jaundice or hypertension occurs. Hepatic impairment. Not for use in stopping active preterm labor or for use in postmenopausal women. Pregnancy (Cat.B) (limited data on 1st trimester use). Nursing mothers: not recommended; discontinue at 37 weeks or upon delivery.
Inj site reactions (pain, swelling, pruritus, nodule), urticaria, nausea, diarrhea; pregnancy-related fetal and maternal complications.
Multidose vial (5mL)—1